Composix Kugel Mesh Product Liability Trial: Thorpe v. Davol and C.R. Bard

Hernia Patch Design Claims, Verdict, and Post-Trial Rulings

Thorpe v. Davol, Inc. and C.R. Bard, Inc. arose from injuries Christopher Thorpe alleged after implantation of an extra-large Composix Kugel hernia patch during a November 2005 hernia repair. The case was part of the federal Kugel Mesh Hernia Repair Patch multidistrict litigation in the U.S. District Court for the District of Rhode Island. The claims focused on the patch’s memory recoil rings, reported ring breaks, warnings, design evidence, medical causation, and complications that included infection, fistula formation, mesh removal, and additional surgery. After a 13-day jury trial, the jury returned a $1.5 million verdict for Christopher and Laure Thorpe, finding against Davol and C.R. Bard on the design claim.

The post-trial proceedings addressed whether the plaintiffs’ medical causation opinions satisfied Daubert, whether the evidence supported inadequate design and warning claims, and whether the defendants were entitled to judgment as a matter of law or a new trial. In its memorandum and order, the court denied the request for a new trial and granted in part and denied in part the defendants’ post-trial motion. The case centered on the implanted hernia patch’s design, the warnings provided with the device, Davol’s recall history, Thorpe’s alleged bowel-related complications, and the damages awarded after trial. Broader Kugel mesh settlement materials later placed the Thorpe verdict within the larger Composix Kugel litigation, which involved thousands of claims and settlement offers tied to alleged complications from the same hernia patch line.

Key Developments in Thorpe v. Davol and C.R. Bard Kugel Mesh Product Liability Litigation

1996–2002: Composix Kugel Patch Development and Market Background

The Kugel hernia patch had been cleared as a medical device by the FDA in 1996, before Davol acquired the product line from Surgical Sense Inc. in 2000. Davol later developed the Composix Kugel Patch with polypropylene mesh, an ePTFE layer, and a PET memory recoil ring intended to help the patch open and remain flat after placement. The extra-large Composix Kugel Patch was first sold in 2002 and later became the device at issue in Thorpe’s lawsuit.

October 2003: Davol Responds to Reported Ring Breaks

Davol first learned of a ring break in its Composix Kugel Patch product line in 2003. Its field assurance department reviewed reported claims, manufacturing records, and available customer information. In October 2003, Davol decided to increase weld-strength testing for memory recoil rings, while the design specification itself remained unchanged.

November 17, 2005: Thorpe Receives Extra-Large Composix Kugel Patch

Christopher Thorpe underwent surgery for an incisional hernia after his surgeon found that the hernia was larger than expected. The surgeon used an extra-large 8-by-10-inch Composix Kugel Patch through a sublay or underlay technique below the muscle layer. This implantation later became central to claims involving design, warnings, causation, bowel-related injury, and medical-device complications.

December 28, 2005: Davol Issues Urgent Product Recall for XL CK Patch

Davol issued an urgent recall for certain extra-large Composix Kugel Patch product codes after reports that the PET recoil ring could break. The recall notice stated that ring breakage could potentially lead to bowel perforation or chronic enteric fistulas. This recall history became part of the later product liability claims involving alleged design and warning defects.

2006: Davol Investigates Ring Break Complaints and IFU Issues

Davol conducted a supplemental failure investigation that reviewed manufacturing data, customer complaints, and the instructions for use packaged with the product. The investigation found that ring breakage had not been identified as a potential failure mode in the earlier design failure analysis for the device. Davol’s final assessment tied the most probable root cause of ring breaks to stresses during folding and insertion of extra-large Composix codes that could cause the recoil-ring weld to break.

October 2007–April 2008: Thorpe Develops Infection, Fistula, and Mesh Removal Complications

Thorpe later experienced abdominal pain, fever, infection, wound complications, and an enterocutaneous fistula. In April 2008, surgery at Duke University Medical Center removed the XL Composix Kugel Patch after the mesh was found folded, with polypropylene exposed to the bowel. The medical history became central to causation arguments over whether the broken ring, mesh condition, adhesions, and bowel contact caused Thorpe’s injuries.

November 25, 2008: Thorpe Case Opens With Federal Complaint Against Davol

Christopher and Laure Thorpe opened the individual federal case by filing a diversity-based complaint against Davol. The complaint asserted claims that included negligence, strict product liability, failure to warn, misrepresentation-based claims, and loss of consortium. The allegations focused on whether the Composix Kugel Patch was unsafe as designed, whether warnings and instructions were adequate, and whether the memory recoil ring could withstand foreseeable stresses in the body.

December 4, 2008: Thorpe Case Joins Federal Kugel Mesh MDL

The Thorpe case was consolidated with the federal Kugel Mesh Hernia Patch multidistrict litigation in the District of Rhode Island. It was later selected as the second of four agreed bellwether cases. That procedural step moved the case from an individual complaint into a coordinated federal litigation structure involving many similar medical-device claims.

June 25, 2010: Pretrial Motions Address Expert Causation and Design Opinions

About six weeks before trial, the parties filed motions in limine concerning expected testimony and evidence. Davol sought to limit opinions from plaintiffs’ medical expert witness Dr. Stephen Ferzoco and biomaterials engineering expert witness Dr. Paul Ducheyne, including opinions related to scar contracture, ring breakage, and the device’s condition. The plaintiffs responded that their expert opinions were grounded in medical, biomaterials, and device evidence relevant to the claimed injury mechanism.

August 23, 2010: Jury Returns $1.5 Million Thorpe Verdict

After trial, the jury returned a verdict in favor of Christopher and Laure Thorpe. The jury found that Davol failed to provide adequate warnings or instructions, acted unreasonably in designing the Composix Kugel Patch, and that Davol’s conduct caused injury and loss-of-consortium damages. The reported award was $1.5 million, while the punitive-damages claim was dismissed after the verdict. The court later granted Davol judgment as a matter of law on the inadequate-warning claim, so the warning finding should be treated as part of the jury verdict but not as a post-trial surviving claim.

February 4, 2011: Court Issues Post-Trial Resolution in Thorpe Case

The court addressed Davol’s post-trial motions for judgment as a matter of law or, alternatively, a new trial. The court granted Davol judgment as a matter of law on the inadequate-warning claim, but denied judgment as a matter of law on the inadequate-design claim and Laure Thorpe’s loss-of-consortium claim. The court also denied Davol’s Rule 59 request for a new trial and conditionally denied a new trial under Rule 50(c), leaving the verdict in place except for the inadequate-warning claim.

July 6, 2011: Broader Kugel Mesh Settlement Offers Follow Bellwether Trials

After the Thorpe verdict and another federal bellwether trial, C.R. Bard extended settlement offers totaling approximately $184 million across about 2,600 Kugel mesh lawsuits. The settlement materials described alleged complications involving bowel perforation, sepsis, intestinal fistulas, and abdominal abscess formation tied to Composix Kugel Mesh hernia patches. This event belongs to the broader Kugel mesh litigation context, not the exact closing date of the individual Thorpe case.

Expert Witness Roles in the Composix Kugel Mesh Product Liability Litigation

1. Medical Causation Expert Witness (Plaintiff)

   Dr. Stephen Ferzoco was identified in the court record as the plaintiffs’ medical expert witness. The defendants sought to exclude testimony that was not referenced in his report and first deposition, including opinions related to scar contracture and memory recoil ring breakage. The plaintiffs described his opinions as addressing the use of hernia mesh prostheses and alleged defects in the Composix Kugel Patch implanted in Thorpe. To avoid overstatement, his role should be framed as offering medical opinions that were challenged by Davol and reviewed by the court.

2. Biomaterials Engineering and Medical Device Expert Witness (Plaintiff)

   Dr. Paul Ducheyne was identified in the court record as the plaintiffs’ biomaterials engineering expert witness. Davol challenged opinions related to scar contracture, ring breakage, and whether the ring welds in Thorpe’s patch were sufficient in strength. The court discussed his background in biomaterial engineering and medical devices, his review of the explanted patch and photographs, and his opinion evidence related to tissue response to implanted medical devices.

3. Product Liability Expert Witness

   A product liability expert witness is often engaged to evaluate alleged design defects, warning adequacy, safer alternatives, complaint history, and recall-related evidence. In a hernia patch case, this expert may help explain whether device design, risk communication, and post-market actions are consistent with product-safety principles.

4. Human Factors Expert Witness

   A human factors expert witness is often engaged when warnings, instructions, user behavior, and foreseeable use are disputed. In a hernia mesh case, this expert may review instructions for use, surgeon-facing materials, product handling steps, and whether risk information was communicated in a way users could reasonably understand and apply.

Product Liability Litigation Insights from Thorpe v. Davol and C.R. Bard

1. Build the design-defect theory around the device’s actual failure mode.

   The Thorpe litigation centered on whether the Composix Kugel Patch’s memory recoil ring and weld strength could withstand foreseeable stresses during folding, insertion, and implantation. Attorneys handling product liability claims involving implanted medical devices should connect the alleged design issue to the specific injury pathway, not just to broad device-risk allegations.

2. Treat warnings and instructions as core trial evidence, not secondary issues.

   The case involved disputes over whether the instructions for use adequately communicated folding technique, placement concerns, and risks tied to ring breakage. In medical-device litigation, warning and instruction evidence can be as important as design evidence because it affects surgeon use, foreseeable handling, and causation defenses.

3. Prepare expert causation opinions for Daubert and post-trial review.

   Davol challenged the plaintiffs’ medical and biomaterials opinions, including issues involving scar contracture, ring breakage, weld strength, and injury causation. Attorneys should make sure expert opinions are tied to the medical record, device evidence, scientific method, and the specific facts of the implant and explant history.

4. Use the treatment timeline to connect device condition, injury, and damages.

   Thorpe’s medical history involved implantation, later infection, fistula issues, mesh removal, and additional surgery. A clear treatment timeline helps attorneys explain causation and damages in a way that is understandable to both the court and jury, especially when product liability claims involve delayed complications after implantation.

5. Separate the individual verdict from the broader MDL settlement context.

   The Thorpe case reached a jury verdict and later post-trial rulings, while the larger Kugel mesh litigation moved toward settlement offers covering thousands of related claims. Attorneys should keep the individual case outcome distinct from MDL-wide settlement developments to avoid confusing verdict facts, procedural posture, and broader resolution context.

Conclusion

Thorpe v. Davol, Inc. and C.R. Bard, Inc. centered on claims that an extra-large Composix Kugel hernia patch failed after implantation, leading to infection, fistula complications, mesh removal, and additional surgery. The case moved through the Kugel Mesh MDL, reached a jury verdict for Christopher and Laure Thorpe, and later involved post-trial rulings addressing expert opinion challenges, design-defect evidence, loss of consortium, the inadequate-warning claim, and Davol’s request for a new trial. As a product liability matter involving an implanted medical device, the litigation turned on the relationship between device design, memory recoil ring performance, instructions for use, recall history, medical causation, and damages. The later broader settlement activity placed the Thorpe verdict within the larger Composix Kugel litigation, while the individual case remained tied to its trial record and post-trial resolution.